Recommends monitoring the lipid profile at diagnosis and periodically thereafter to identify dyslipidemia in adult patients with Cushing syndrome. Triggered by phrases such as "Patient diagnosed with Cushing syndrome", "Assessing for lipid abnormalities in endocrine disorder", or "Screening for dyslipidemia in cortisol excess".
Installs into .claude/skills of the current project.
Are you the author of Endo Monitor Lipid Profile Cushing Syndrome Dyslipidemia?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-monitor-lipid-profile-cushing-syndrome-dyslip)
---
name: endo-monitor-lipid-profile-cushing-syndrome-dyslipidemia
description: Recommends monitoring the lipid profile at diagnosis and periodically thereafter to identify dyslipidemia in adult patients with Cushing syndrome. Triggered by phrases such as "Patient diagnosed with Cushing syndrome", "Assessing for lipid abnormalities in endocrine disorder", or "Screening for dyslipidemia in cortisol excess".
---
# Monitor lipid profile to identify dyslipidemia in Cushing syndrome
## STEP 1 — Gather Information
Obtain a lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) at the time of Cushing syndrome diagnosis and periodically thereafter as determined by the treating physician. Use fasting or nonfasting samples; repeat fasting if triglycerides are elevated or genetic dyslipidemia suspected.
## STEP 2 — Rule In / Rule Out
Rule in dyslipidemia if any lipid parameter exceeds normal ranges: LDL-C >70 mg/dL, triglycerides >150 mg/dL, HDL-C <40 mg/dL in men or <50 mg/dL in women. Rule out dyslipidemia if all parameters are within normal limits.
## STEP 3 — Classify or Stratify
If dyslipidemia is present, assess atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations and consider risk-enhancing factors (e.g., visceral obesity, hypertension, diabetes, elevated lipoprotein[a]).
## STEP 4 — Decide
If dyslipidemia is identified, advise lifestyle modification and consider statin therapy as adjunct to reduce cardiovascular risk, per guideline 7.2; if lipids remain normal, continue routine monitoring at physician discretion.
## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on total cholesterol; evaluate all lipid components. Avoid initiating statin therapy without confirming LDL-C >70 mg/dL, especially when patients are on ketoconazole (which increases statin levels and myopathy risk). Do not assume lipid-lowering therapy is appropriate for patients with limited life expectancy (e.g., underlying malignancy). Remember that triglycerides >500 mg/dL contraindicate bile acid sequestrants.
## Concrete Clinical Example
A 45-year-old woman with newly diagnosed adrenal adenoma–causing Cushing syndrome presents for initial evaluation. Lipid panel shows LDL-C 130 mg/dL, triglycerides 200 mg/dL, HDL-C 35 mg/dL. Dyslipidemia is ruled in; she is advised on diet and exercise, and statin therapy is considered after discussing risks/benefits.
**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674
